Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It raised $290 million in September and $350 million in October of that year. Ginkgo Bioworks went public on the New York Stock Exchange via a SPAC merger on September 17, 2021.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| DNA | Ginkgo Bioworks Holdings, Inc. | 2026-03-03 04:32:41 | 6.88 | -0.18 | -2.62 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DNA | 0001830214 | Ginkgo Bioworks Holdings, Inc. | US37611X2099 | — | 872652913 | NYSE | 2836 | Biological Products, (No Diagnostic Substances) | 1231 | DE | 27 DRYDOCK AVENUE | BOSTON | MA | 02210 | UNITED STATES | US | (877) 442-5362 | 27 DRYDOCK AVENUE, BOSTON, MA, 02210 | 27 DRYDOCK AVENUE, BOSTON, MA, 02210 | Soaring Eagle Acquisition Corp. | Biotechnology | 2008 | Jason Kelly | 834 | http://ginkgobioworks.com | 617,000,000 | 60,256,369 | — | Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It raised $290 million in September and $350 million in October of that year. Ginkgo Bioworks went public on the New York Stock Exchange via a SPAC merger on September 17, 2021. | 2026-02-26 18:36:25 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 553,000,000 | -64,000,000 | -10.3728 | — | — | — |
| 2024 | 617,000,000 | -1,816,000,000 | -74.6404 | — | — | — |
| 2023 | 2,433,000,000 | 41,000,000 | 1.714 | — | — | — |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Mark Dmytruk | Chief Financial Officer | 2024 | 460,000 | — | 1,320,000 | — | 0 | 1,780,000 |
| Reshma Shetty | Chief Operating Officer, President | 2024 | 250,000 | — | 0 | — | 0 | 1,231,000 |
| Jason Kelly | Chief Executive Officer | 2024 | 250,000 | — | 0 | — | 0 | 1,231,000 |
| Jason Kelly | Chief Executive Officer | 2023 | 250,000 | — | 0 | — | 12,500 | 262,500 |
| Mark Dmytruk | Chief Financial Officer | 2023 | 460,000 | — | 1,218,000 | — | 16,500 | 1,694,500 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 485 |
| 2024 | 834 |
| 2023 | 1,218 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 170,155,000 | 227,043,000 | 251,455,000 |
| Cost Of Revenue | 31,521,000 | 38,549,000 | 7,481,000 |
| Gross Profit | — | — | — |
| Research And Development Expenses | 243,773,000 | 424,061,000 | 580,621,000 |
| General And Administrative Expenses | 183,290,000 | 246,161,000 | 385,025,000 |
| Operating Expenses | 485,433,000 | 786,800,000 | 1,115,861,000 |
| Operating Income | -315,278,000 | -559,757,000 | -864,406,000 |
| Net Income | -312,763,000 | -547,029,000 | -892,869,000 |
| Earnings Per Share Basic | -5.64 | -10.54 | -0.46 |
| Earnings Per Share Diluted | -5.64 | -10.54 | -0.46 |
| Weighted Average Shares Outstanding Basic | 55,457,676 | 51,894,639 | 1,944,420,000 |
| Weighted Average Shares Outstanding Diluted | 55,457,676 | 51,894,639 | 1,944,420,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 167,202,000 | 561,572,000 | 944,073,000 |
| Marketable Securities Current | 255,418,000 | — | — |
| Accounts Receivable | 229,000 | 586,000 | 742,000 |
| Inventories | — | — | 46,000 |
| Non Trade Receivables | — | — | 1,546,000 |
| Other Assets Current | — | — | 362,000 |
| Total Assets Current | 471,838,000 | 602,744,000 | 1,001,749,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 167,783,000 | 203,720,000 | 188,193,000 |
| Other Assets Non Current | 47,167,000 | 55,336,000 | 58,055,000 |
| Total Assets Non Current | 647,858,000 | 774,705,000 | 663,593,000 |
| Total Assets | 1,119,696,000 | 1,377,449,000 | 1,665,342,000 |
| Accounts Payable | 10,566,000 | 14,169,000 | 9,323,000 |
| Deferred Revenue | 18,946,000 | 27,710,000 | 44,486,000 |
| Short Term Debt | — | — | — |
| Other Liabilities Current | — | — | — |
| Total Liabilities Current | 95,970,000 | 107,266,000 | 163,860,000 |
| Long Term Debt | — | — | — |
| Other Liabilities Non Current | 22,876,000 | 16,576,000 | 18,733,000 |
| Total Liabilities Non Current | 515,136,000 | 554,125,000 | 404,330,000 |
| Total Liabilities | 611,106,000 | 661,391,000 | 568,190,000 |
| Common Stock | 6,000 | 5,000 | 199,000 |
| Retained Earnings | -6,150,320,000 | -5,837,557,000 | -5,290,528,000 |
| Accumulated Other Comprehensive Income | 1,851,000 | -1,806,000 | 1,484,000 |
| Total Shareholders Equity | 508,590,000 | 716,058,000 | 1,097,152,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 58,990,000 | 63,020,000 | 70,507,000 |
| Share Based Compensation Expense | 81,546,000 | 112,344,000 | 229,884,000 |
| Other Non Cash Income Expense | -2,064,000 | -1,224,000 | -2,147,000 |
| Change In Accounts Receivable | 1,473,000 | 4,725,000 | -50,068,000 |
| Change In Inventories | — | — | — |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | -2,992,000 | 4,771,000 | -1,183,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | -171,059,000 | -319,585,000 | -295,500,000 |
| Purchases Of Marketable Securities | 418,630,000 | — | — |
| Sales Of Marketable Securities | 25,899,000 | 4,519,000 | — |
| Acquisition Of Property Plant And Equipment | 7,665,000 | 62,541,000 | 40,801,000 |
| Acquisition Of Business | 0 | 5,400,000 | 0 |
| Other Investing Activities | -50,000 | -538,000 | 990,000 |
| Cash From Investing Activities | -240,289,000 | -62,236,000 | -80,693,000 |
| Tax Withholding For Share Based Compensation | 0 | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 19,469,000 | — | — |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | 200,000 |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 17,775,000 | -1,739,000 | -3,216,000 |
| Change In Cash | -393,372,000 | -383,841,000 | -379,997,000 |
| Cash At End Of Period | 167,202,000 | 561,572,000 | 944,073,000 |
| Income Taxes Paid | 192,000 | 894,000 | 670,000 |
| Interest Paid | 4,000 | 32,000 | 83,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | -5.64 | -10.54 | -0.46 |
| Price To Earnings Ratio | -1.4734 | -0.9317 | -146.9565 |
| Earnings Growth Rate | -46.4896 | 2,191.3043 | -63.2 |
| Price Earnings To Growth Ratio | 0.0317 | -0.0004 | 2.3253 |
| Book Value Per Share | 9.1708 | 13.7983 | 0.5643 |
| Price To Book Ratio | 0.9061 | 0.7117 | 119.8036 |
| Ebitda | -253,581,000 | -483,021,000 | -821,599,000 |
| Enterprise Value | — | — | — |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | — | — | — |
| Capital Expenditures | 23,053,000 | 78,547,000 | -56,073,000 |
| Free Cash Flow | -194,112,000 | -398,132,000 | -239,427,000 |
| Return On Equity | -0.615 | -0.7639 | -0.8138 |
| One Year Beta | 1.9949 | 2.988 | 3.1752 |
| Three Year Beta | 2.4938 | 2.7022 | 2.4585 |
| Five Year Beta | 2.385 | 2.5305 | 2.4585 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Coen Steven P. | — | 2026-01-20 | 972 | D | 8,321 |
| Coen Steven P. | — | 2026-01-16 | 587 | A | 8,075 |
| Coen Steven P. | — | 2026-01-16 | 156 | A | 8,231 |
| Coen Steven P. | — | 2026-01-16 | 1,062 | A | 9,293 |
| Coen Steven P. | — | 2026-01-16 | 587 | D | 9,405 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Wealth Preservation Advisors, LLC | 2025-12-31 | 416 | 50 | 8.32 |
| Sunbelt Securities, Inc. | 2025-12-31 | 291 | 35 | 8.3143 |
| Invesco Ltd. | 2025-12-31 | 2,174,777 | 261,706 | 8.31 |
| SB INVESTMENT ADVISERS (UK) LTD | 2025-12-31 | 5,075,158 | 610,729 | 8.31 |
| Coastal Bridge Advisors, LLC | 2025-12-31 | 2,300,349 | 276,817 | 8.31 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| PIMCO Equity Series | 2025-12-31 | Class A | PMJAX | 341,988 | 2,841,920.28 | 0.0945 |
| PIMCO Equity Series | 2025-12-31 | I-2 | PMJPX | 341,988 | 2,841,920.28 | 0.0945 |
| PIMCO Equity Series | 2025-12-31 | Institutional Class | PMJIX | 341,988 | 2,841,920.28 | 0.0945 |
| RYDEX SERIES FUNDS | 2025-12-31 | Class C | RYCMX | 55 | 457.05 | 0.0054 |
| RYDEX SERIES FUNDS | 2025-12-31 | Class A | RYAKX | 55 | 457.05 | 0.0054 |